If the last 15 months have taught us anything, it’s that no one really knows what the future holds. But that doesn’t mean you can’t prepare for it.
With the frequency, quality, content, and channels of HCP engagement changing significantly, getting ready to go ‘back to normal’ could be a very risky move for pharma companies.
In part 1 of our white paper, we explore HCP engagement trends through research by Sermo, Accenture, and STEM Healthcare, an Ashfield Advisory company. We contextualize these results with our own insights and opinions, before offering key learnings about how you can rethink your sales strategy, review your channel mix, and reconsider how to resource your teams.
Did you know?
88% of HCPs surveyed said they still want to hear about new treatments despite the pandemic.
Phone calls that open with a patient hook are more than 5x as likely to result in a ‘good’ selling outcome.
HCPs expect the share of remote interactions in a year’s time to be double what they were before COVID-19.
Download our white paper to find out more.
*As Part 2 of this white paper is now available you will automatically receive both parts. Part 2 builds on the key insights from our first paper, offering practical advice for engaging with HCPs in the new healthcare landscape.